Lipid Nanoparticles for mRNA Delivery: Key Concepts and Safety Considerations

Core Components of Lipid Nanoparticles (LNPs)

• Four main components: ionizable lipids, phospholipids, cholesterol, and PEGylated lipids.

• Function: enable cargo encapsulation, protection from nucleases, cellular uptake, endosomal escape, and circulation stability.

• Ionizable lipids

  • Neutral in circulation; protonate in acidic endosomes to promote endosomal escape.

  • Key property: pKa tuning; at physiological pH ~$pH \approx 7.4$ the lipids are neutral; in endosomes with $pH \in [5.5, 6.3]$ they become positively charged to disrupt the endosomal membrane.

  • Stereochemistry matters: stereopure ionizable lipids can greatly improve delivery; example: stereopure C12-200-S LNPs delivered up to $6.1\text{-fold}$ more mRNA in vivo than racemic/C12-200-R controls.

  • Multi-tail ionizable lipids (cone-shaped) enhance endosomal membrane disruption.

• Cholesterol

  • Stabilizes bilayer, modulates fluidity and permeability for robust encapsulation and protection.

  • Derivative optimization (e.g., 7α-hydroxycholesterol) can improve delivery: substituting $25\%$ or $50\%$ of cholesterol yielded delivery improvements of $1.8\text{-fold}$ and $2.0\text{-fold}$ in primary human T cells ex vivo by promoting endosomal recycling changes.

  • Cationic cholesterol can alter organ tropism (lung/heart focus).

• Phospholipids

  • Examples: DSPC and DOPE; truncated cone-like shape with smaller headgroups aid membrane fusion and cargo release.

• PEGylated lipids

  • Increase colloidal stability and circulation time; reduce aggregation and opsonization.

  • PEG immunogenicity: anti-PEG antibodies can develop after repeated dosing, causing accelerated blood clearance (ABC) and reduced efficacy.

  • Tuning: PEG chain length, architecture, and lipid fragment composition affect performance; cleavable PEG variants can mitigate ABC.

• Organ targeting and SORT concept

  • Liver targeting often relies on ApoE adsorption and LDLR uptake; GalNAc ligands target ASGPR for hepatocytes.

  • SORT (Selective Organ Targeting) system uses four lipid classes to bias biodistribution after IV administration: cationic (lung), anionic (spleen), ionizable amino lipids (liver), and others to tune surface properties.

  • Examples: lung targeting with cationic lipids; spleen targeting with anionic lipids; liver targeting with ionizable lipids; kidney targeting achieved with DOTAP-containing formulations (e.g., DOTAP-50) delivering notable kidney uptake (~$13\%$ of the dose).

  • Brain targeting strategies include surface ligands (e.g., transferrin, lactoferrin) for receptor‑mediated transcytosis and ionic liquid coatings enabling RBC hitchhiking, then release at the brain endothelium.

• Applications and examples

  • LNPs enable organ-specific delivery for mRNA therapies and vaccines; several organ-targeting LNPs and SORT variants have shown tissue- and cell-type–specific delivery (e.g., bone marrow, lungs, spleen, kidneys).

  • Nebulized LNPs offer direct lung delivery, bypassing some systemic barriers.

  • CRISPR-Cas9 and gene-editing payloads have been delivered using LNPs, including multiplexed systems carrying siRNA, Cas9 RNA, and sgRNA for cancer therapy and cystic fibrosis models.

Endosomal Escape: Enhancing Cytosolic Delivery

• Endosomal escape is the bottleneck: about $95\%$ of LNPs are taken up by cells, but <$2\%$ of delivered mRNA escapes endosomes to reach the cytoplasm.

• Mechanisms

  • Proton sponge effect: buffering by ionizable lipids causes endosomal swelling and rupture via chloride influx, aiding cargo release. Endosomal pH drives protonation and membrane perturbation.

  • Membrane disruption and non-bilayer phases: cone-shaped ionizable lipids interact with endosomal lipids to form hexagonal HII phases, destabilizing membranes and enabling cargo release.

  • Topology matters: lamellar LNPs face higher energy barriers to fusion than cuboplex or inverse hexagonal LNPs, which support fusion pores for release.

• Nanomechanical approaches

  • Lipid-based nanoscale molecular machines (LNM) with azobenzene lipidoids can, under light, destabilize endo-lysosomal membranes to release cargo.

• Design implications

  • Improving endosomal escape improves bioavailability and can reduce required doses, potentially alleviating safety concerns.

Toxicity, Reactogenicity, and Immunogenicity

• Ionizable lipids

  • Essential for delivery but can participate in signaling and immune activation; can trigger TLRs (notably TLR4) and induce pro-inflammatory cytokines (e.g., $IL-6,<br>$CCL2, $CXCL2) in some formulations (e.g., DLin-MC3-DMA, C12-200).</p></li><li><p>Metabolites (fatty acids) can activate PPAR pathways, contributing to inflammation and liver toxicity.</p></li></ul></li><li><p>PEGylated lipids</p><ul><li><p>Repeated dosing can induce anti-PEG antibodies, causing ABC and altered pharmacokinetics and safety concerns.</p></li></ul></li><li><p>Lysosomal cysteine proteases</p><ul><li><p>Cathepsins B/D can be released upon lysosomal membrane permeabilization, promoting inflammation via NLRP3 inflammasome and contributing to cytotoxicity.</p></li></ul></li><li><p>Off-target effects from cargo</p><ul><li><p>mRNA may cause off-target protein expression and innate immune activation; degraded RNA fragments can act as DAMPs, triggering inflammation.</p></li></ul></li><li><p>Strategies to reduce toxicity</p><ul><li><p>Replace ionizable lipids with biodegradable components (e.g., trehalose glycolipids) to yield non-toxic metabolites; LNPs with trehalose glycolipids (LNP S050L) showed lower organ toxicity with equivalent immunogenicity.</p></li><li><p>Replace PEG with polysarcosine (pSar) to reduce proinflammatory cytokine secretion and lower CARPA risk, enabling PEG-free safety improvements while maintaining protein expression.</p></li><li><p>Modulate lipid composition (lower ionizable lipid content, use cleavable PEG variants like PEG-CHMC, CHEMS, CHST) to reduce ABC and inflammatory risk.</p></li></ul></li></ul><h3 id="8470b418-8220-466e-a16f-feadaa64c05f" data-toc-id="8470b418-8220-466e-a16f-feadaa64c05f" collapsed="false" seolevelmigrated="true">Reactogenicity and Immunogenicity</h3><ul><li><p>Reactogenicity reflects local and systemic inflammatory responses to vaccines</p><ul><li><p>Local: swelling, redness, pain, heat at injection site; more common with mRNA vaccines than placebo.</p></li><li><p>Systemic: fatigue, headache, fever, myalgia; typically more pronounced after the second dose and in younger individuals.</p></li><li><p>Severe events (e.g., myocarditis, anaphylaxis) are rare but clinically significant; anaphylaxis linked to PEG-associated reactions and cytokine cascades (e.g., IL-1, IL-6).</p></li></ul></li><li><p>Role of innate sensing</p><ul><li><p>Unmodified RNA can activate TLR3, TLR7, TLR8 and other sensors (e.g., MDA5), triggering innate immunity and systemic inflammation; pseudouridine modifications reduce but do not eliminate immunogenicity.</p></li></ul></li><li><p>Adjuvant strategies to boost immunogenicity</p><ul><li><p>Adjuvant lipidoids with TLR7/8 agonistic activity can enhance innate and adaptive responses (Th1 bias, robust neutralizing antibodies, durable B and T cell responses).</p></li><li><p>Intrinsic adjuvants: lipid formulations combined with mRNA and TLR agonists can improve antigen presentation and dendritic cell activation.</p></li><li><p>Adjuvants such as PAM3CSK4 (lipopeptide) and LPS (TLR4 agonist) can boost CD8+ T-cell responses and antitumor activity.</p></li></ul></li><li><p>Balancing immunogenicity and safety</p><ul><li><p>Fine-tuning ionizable lipid, phospholipid, cholesterol, and PEG composition; using cleavable PEG to reduce ABC; controlling particle size and surface charge to balance efficacy and safety.</p></li><li><p>Route and formulation choices influence immunogenicity: IV often yields stronger systemic T-cell responses; intranasal can generate mucosal immunity (IgA) in addition to systemic responses.</p></li></ul></li><li><p>Route considerations and delivery strategies</p><ul><li><p>IV delivery mobilizes APCs in spleen/lymphoid tissues, enhancing systemic T-cell responses.</p></li><li><p>IN (intra-nasal) delivery can provide mucosal immunity but requires careful safety and delivery optimization.</p></li></ul></li><li><p>Long-term immunogenicity gaps</p><ul><li><p>Most studies focus on short-term responses; long-term immune tolerance, chronic inflammation, and effects of repeated dosing require more study.</p></li></ul></li></ul><h3 id="ef099ec9-9a35-42f4-ac58-acdee368e12b" data-toc-id="ef099ec9-9a35-42f4-ac58-acdee368e12b" collapsed="false" seolevelmigrated="true">Organ Targeting, Delivery Strategies, and SORT</h3><ul><li><p>Liver targeting and beyond</p><ul><li><p>ApoE adsorption promotes hepatocyte uptake via LDLR; GalNAc ligands target ASGPR for liver-specific uptake.</p></li><li><p>SORT system expands beyond liver to other organs by adjusting lipid compositions to bias biodistribution.</p></li></ul></li><li><p>SORT-enabled organ targeting</p><ul><li><p>Lung targeting: cationic lipids</p></li><li><p>Spleen targeting: anionic lipids</p></li><li><p>Liver targeting: ionizable amino lipids</p></li><li><p>Kidney targeting: DOTAP-containing formulations (e.g., DOTAP-50) achieve notable kidney delivery (~$13\%$$ of dose).

  • Brain targeting: ligands (e.g., transferrin, lactoferrin) enable receptor-mediated BBB transcytosis; ionic liquids can enable RBC hitchhiking for brain delivery.

• Applications enabled by SORT

  • In vivo genome editing in lung stem cells with durable correction; CAR T cells generated in vivo in spleen; kidney-targeted RNAi and gene silencing demonstrated via SORT LNPs; bone targeting via bisphosphonate lipid-like materials and ApoE-dependent homing.

• CRISPR-Cas9 and multiplexed mRNA delivery

  • LNPs can co-deliver siRNA, Cas9 mRNA, and sgRNA to enable tumor editing and therapy; demonstrated in cancer and CF models with tissue-specific delivery.

Adjuvants, Formulation, and Manufacturing Considerations

• Adjuvants and intrinsic adjuvant properties

  • Incorporating adjuvant lipidoids or TLR agonists can enhance immunogenicity and antigen presentation, supporting stronger vaccine responses.

• Formulation strategies to reduce safety risks

  • Cleavable PEG derivatives to mitigate ABC;

  • Biocompatible lipid designs (e.g., zwitterionic lipids) to improve biocompatibility;

  • PEG-free platforms (e.g., pSar-functionalized LNPs) to reduce anti-PEG responses while maintaining efficacy.

• Manufacturing and regulatory considerations

  • Thousands of lipid variants exist; a robust regulatory framework is needed to standardize manufacturing, safety evaluation, and quality control for LNPs.

Routes of Administration and Practical Considerations

• Administration routes

  • IV: broad biodistribution; strong systemic immune responses.

  • IM/SC/ID: conventional for vaccines; dose-sparing considerations; potential for localized responses.

  • IN and nebulized routes: mucosal and airway delivery; potential for noninvasive vaccination and targeted delivery to respiratory tissues.

  • Needle-free options (e.g., PYRO liquid jet) can localize mRNA delivery to APC-rich skin layers, reducing systemic reactogenicity while maintaining immunogenicity.

• Naked mRNA vs LNP-delivered mRNA

  • Naked mRNA via needle-free approaches can minimize systemic reactogenicity but requires rapid uptake by APCs and robust local expression.

• Implications for safety and efficacy

  • Balancing endosomal escape, organ targeting, and immunogenicity is essential to maximize efficacy while minimizing adverse effects.

Summary and Outlook

• Targeted, safe, and effective LNPs require:

  • Precise organ- and cell-specific targeting with robust in vitro and in vivo evaluation platforms (e.g., microfluidic systems) to predict safety and efficacy.

  • Active targeting strategies with surface ligands while maintaining manufacturability at scale.

  • Biocompatible lipid designs (e.g., zwitterionic or biodegradable lipids) to reduce toxicity.

  • Enhanced endosomal escape mechanisms to improve cytosolic delivery and lower required doses.

  • Regulatory frameworks to manage the expanding diversity of LNPs and lipids, ensuring standardized safety evaluation and manufacturing.

• Future directions

  • Further development of SORT and organ-specific LNPs to broaden therapeutic applications beyond liver-targeted therapies.

  • Improved understanding of long-term immunogenicity and safety with repeated dosing, especially for chronic diseases and genetic disorders.

  • Optimization of routes and formulations to maximize safety, efficacy, and patient accessibility.